Stockreport

Ocugen to Discontinue Phase 3 oGVHD Trial

Ocugen, Inc.  (OCGN) 
PDF MALVERN, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transforma [Read more]